目的 观察普瑞巴林联合曲马多治疗顽固性带状疱疹后遗神经痛(postherpetic neuralgia,PHN)(病程超过3个月)的疗效和安全性。方法 将56例带状疱疹后神经痛患者随机分成试验组( 30例) 和对照组( 26 例) 。试验组给予普瑞巴林75~150 mg,2次/d,联合曲马多100 mg 2次/d;对照组予曲马多100 mg,2次/d口服,观察时间为6周。采用视觉模拟评分(VAS)评估治疗前及治疗后疼痛程度,同时观察不良反应。结果 经过6周的治疗,两组患者VAS评分均较治疗前降低,试验组较对照组VAS评分降低更明显,差异有统计学意义(P<0.05);试验组有效率为76.7%,对组照有效率为46.1%,两组间差异有统计学意义(P<0.01);治疗期间普瑞巴林联合曲马多存在不良反应,主要表现为头昏、嗜睡及外周水肿等,且与剂量相关。结论 联合应用普瑞巴林和曲马多对于治疗顽固性带状疱疹后神经痛效果好,安全。
Abstract
Objective To evaluate the clinical efficacy and safety of pregabalin combined with tramadol in the treatment of patients with postherpetic neuralgia (PHN) caused by refractory herpes zoster(the pain lasted more than 3 months).Methods Fifty-six patients with PHN caused by refractory herpes zoster were randomly divided into two groups: treatment group (30 patients) and control group (26 patients). The treatment group was given pregabalin, 75-150 mg BID combined with tramadol 100 mg BID for six weeks. The control group received tramadol 100 mgBID for six weeks. The degree of pain before and after treatment was evaluated using the Visual analogue scale (VAS), while the adverse effects were observed.Results After six weeks of treatment, the VAS scores of both groups were significantly deceased, especially in the treatment group (P<0.05).The efficacy in the treatment group (76.7%) was significantly different from that in the control group (46.1%)(P<0.01). In this study, adverse effects of pregabalin were mainly manifested as dizziness, drowsiness and peripheral edema, which were dose related.Conclusions It is safe and effective to treat PHN caused by refractory herpes zoster with pregabalin combined with tramadol.
关键词
普瑞巴林 /
曲马多 /
带状疱疹后神经痛 /
疗效和安全性
Key words
puribalin /
tramadol /
postherpetic neuralgia /
efficacy and safety
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 范永龙,蔡 卉.加巴喷丁联合针灸、通络活血止痛汤治疗带状疱疹后遗神经痛疗效观察[J].江西医药,2011,46(6):561-562.
[2] Wang W Y, Liu S H, Lin M Y, et al. Initial presentation sites as predictors of herpes zoster complications: a nationwide cohort study[J]. PLoS One, 2016, 11(10): e0164019.
[3] Mallick-Searle T, Snodgrass B, Brant J M. Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology[J]. J Multidiscip Healthc, 2016, 2016(9): 447-454.
[4] Dworkin R H, O’Connor A B, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update [J]. Mayo Clin Proc, 2010, 85(3 Suppl): S3-14.
[5] Hadley G R, Gayle J A, Ripoll J, et al. Post-herpetic Neuralgia: a review [J]. Curr Pain Headache Rep, 2016, 20(3): 17.
[6] Gan E Y, Tian E A, Tey H L. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol, 2013, 14(2):77-85.
[7] Choi B, Rowbothara M C. Effect of adrengergic receptor activation on post-herpetic neuralgia pain and sensory disturbances [J]. Pain, 1997, 69(1-2): 55-56.
[8] 皮铎波, 沈迎雁, 岳建宁,等. 椎旁脊神经根阻滞联合普瑞巴林治疗带状疱疹后神经痛的临床疗效[J]. 中国疼痛医学杂志, 2013, 19(2): 127-128.
[9] 陈 嫄, 陈春富. 普瑞巴林耐受不良及成瘾性[J]. 国际神经病学神经外科学杂志, 2014, 41(2): 189-192.
[10] Semel D, MurphyT K, Zlateva G, et al. Evalution of the safety and efficacy of pregabalin in older patients with neropathic pain: results from a pooled analysis of 11 clinics studies [J]. BMCF Am Pract, 2010, 11(5): 85.
PDF(547 KB)
